Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of SHR-1905 in moderate-to-severe atopic dermatitis
CTR20253993Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1905 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Nov 2025; status: active.
02
Drugs
SHR-1905
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20253993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253993.